Nasdaq-listed biotech firm Sonnet BioTherapeutics has announced a significant strategic shift, forming a business combination with Rorschach to establish Hyperliquid Strategies Inc. (HSI).
Read MoreNasdaq-listed biotech firm Sonnet BioTherapeutics has announced a significant strategic shift, forming a business combination with Rorschach to establish Hyperliquid Strategies Inc. (HSI).
Read More